πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Nektar Therapeutics

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

AnaptysBio, Inc.

AnaptysBio, Inc. logo
Market Cap: Medium
Employees: Low

Imsidolimab, Rosnilimab, ANB032

Anaptys Bio, Inc. is a clinical stage biotechnology company focused on developing therapeutic product candidates for inflammation and immuno-oncology indications. Their products target dermatological inflammatory diseases and other human inflammatory conditions.

Tags: antibody development, biotechnology, immuno-oncology, inflammation, therapeutics

Symbol: ANAB

Recent Price: $13.22

Industry: Biotechnology

CEO: Mr. Daniel R. Faga

Sector: Healthcare

Employees: 117

Address: 10770 Wateridge Circle, San Diego, CA 92121-5801

Phone: 858 362 6295

Last updated: 2024-12-31

Amgen Inc.

Amgen Inc. logo
Market Cap: Highest
Employees: Highest

Enbrel, Neulasta, Prolia, Xgeva, Otezla, Aranesp, KYPROLIS, Repatha, Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide, focusing on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience.

Tags: biotechnology, bone health, cardiovascular, healthcare, inflammation, neuroscience, oncology, pharmaceuticals, therapeutics

Symbol: AMGN

Recent Price: $259.30

Industry: Drug Manufacturers - General

CEO: Mr. Robert A. Bradway

Sector: Healthcare

Employees: 26700

Address: One Amgen Center Drive, Thousand Oaks, CA 91320-1799

Phone: 805 447 1000

Leadership

  • Robert A. Bradway, Chairman and Chief Executive Officer
  • James Bradner, Executive Vice President, Research and Development, and Chief Scientific Officer
  • Sean Bruich, Senior Vice President Artificial Intelligence and Data
  • Paul Burton, Senior Vice President and Chief Medical Officer
  • Raymond Deshaies, Senior Vice President, Global Research
  • Jackie Elbonne, Senior Vice President, Quality and Chief Quality Officer
  • Murdo Gordon, Executive Vice President, Global Commercial Operations
  • Jonathan Graham, Executive Vice President and General Counsel and Secretary
  • Peter Griffith, Executive Vice President and Chief Financial Officer
  • Nancy Grygiel, Senior Vice President, Worldwide Compliance & Business Ethics and Chief Compliance Officer
  • Narimon Honarpour, Senior Vice President, Global Development
  • Vikram Karnani, Executive Vice President, and President, Global Commercial Operations and Medical Affairs (Rare Disease)
  • My Linh Kha, Senior Vice President and General Manager, Japan Asia-Pacific
  • Rachna Khosla, Senior Vice President, Business Development
  • Gilles Marrache, Senior Vice President, Regional General Manager
  • Derek Miller, Senior Vice President, Human Resources
  • Jerry Murry, Senior Vice President, Process Development
  • Kave Niksefat, Senior Vice President, Global Marketing and Access
  • Arleen Paulino, Senior Vice President, Manufacturing
  • Annalisa Pizzarello, Senior Vice President, Results Delivery Office
  • Greg Portner, Senior Vice President, Global Government Affairs and Policy
  • Anton Rabushka, Senior Vice President, Finance
  • Emily Razaqi, Senior Vice President, Obesity and Related Conditions
  • David M. Reese, Executive Vice President and Chief Technology Officer
  • Esteban Santos, Executive Vice President, Operations
  • Darryl Sleep, Senior Vice President, Global Medical
  • Jean-Charles Soria, Senior Vice President, Research and Development
  • Susan Sweeney, Executive Vice President, Obesity and Related Conditions
  • Mark J. Taisey, Senior Vice President, Global Regulatory Affairs and Strategy
  • Susie Tappouni, Head of Corporate Affairs
  • Ian Thompson, Senior Vice President, U.S. Business Operations
  • Brenda Torres, Senior Vice President, Global Supply Chain
  • Alper Üreten, Vice President, Commercialization and Program Management
  • Wanda M. Austin, Retired President and Chief Executive Officer, The Aerospace Corporation
  • Michael V. Drake, President, University of California
  • Brian J. Druker, Physician-Scientist and Professor of Medicine, Oregon Health & Science University (OHSU), Director of the OHSU Knight Cancer Institute and JELD-WEN Chair of Leukemia Research, and Associate Dean for Oncology, OHSU School of Medicine
  • Robert A. Eckert, Lead Independent Director, Chairman Emeritus, Mattel, Inc.
  • Greg C. Garland, Former Executive Chairman and Former Chairman and Chief Executive Officer, Phillips 66
  • Charles M. Holley, Jr., Former Executive Vice President and Chief Financial Officer of Wal-Mart Stores, Inc.
  • S. Omar Ishrak, Former Executive Chairman and Chairman of the Board of Directors, Medtronic plc
  • Tyler Jacks, David H. Koch Professor of Biology, Massachusetts Institute of Technology and Founding Director of the David H. Koch Institute for Integrative Cancer Research
  • Mary E. Klotman, Executive Vice President for Health Affairs of Duke University, Dean of the Duke University School of Medicine, and Chief Academic Officer of Duke Health
  • Ellen J. Kullman, Executive Chair of the Board and Former President and Chief Executive Officer of Carbon, Inc.
  • Amy E. Miles, Former Chair of the Board and Chief Executive Officer, Regal Entertainment Group, Inc.

Last updated: 2024-12-31

Omeros Corporation

Omeros Corporation logo
Market Cap: Low
Employees: Low

Narsoplimab

Omeros Corporation is a commercial-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for inflammation, immune-related cancers, and addictive disorders.

Tags: Narsoplimab, addiction, biopharmaceutical, clinical trials, drug development, immune system, therapeutics

Symbol: OMER

Recent Price: $9.74

Industry: Biotechnology

CEO: Dr. Gregory A. Demopulos M.D.

Sector: Healthcare

Employees: 198

Address: The Omeros Building, Seattle, WA 98119

Phone: 206 676 5000

Last updated: 2024-12-31

Vaccinex, Inc.

Vaccinex, Inc. logo
Market Cap: Lowest
Employees: Lowest

pepinemab

Vaccinex, Inc., a clinical-stage biotechnology company, focuses on developing targeted biotherapeutics for cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical trials for multiple serious conditions.

Tags: autoimmune disorders, biotechnology, biotherapeutics, cancer, clinical trials, neurodegenerative diseases

Symbol: VCNX

Recent Price: $1.11

Industry: Biotechnology

CEO: Dr. Maurice Zauderer Ph.D.

Sector: Healthcare

Employees: 37

Address: 1895 Mount Hope Avenue, Rochester, NY 14620

Phone: 585 271 2700

Last updated: 2024-12-31

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

Zunsemetinib

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune-inflammatory diseases. It operates through Therapeutics and Contract Research segments, addressing unmet needs with innovative therapies, including treatments for rheumatoid and psoriatic arthritis, atopic dermatitis, autoimmune diseases, inflammatory bowel disease, and certain cancers.

Tags: atopic dermatitis, autoimmune diseases, biopharmaceutical, cancer, contract research, drug development, immune-inflammatory diseases, psoriatic arthritis, rheumatoid arthritis, therapeutics

Symbol: ACRS

Recent Price: $2.48

Industry: Medical - Diagnostics & Research

CEO: Dr. Neal S. Walker D.O., M.D.

Sector: Healthcare

Employees: 86

Address: 640 Lee Road, Wayne, PA 19087

Phone: 484 324 7933

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

bluebird bio, Inc.

bluebird bio, Inc. logo
Market Cap: Low
Employees: Medium

betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel

bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

Tags: betibeglogene autotemcel, biotechnology, elivaldogene autotemcel, gene therapy, genetic diseases, lovotibeglogene autotemcel

Symbol: BLUE

Recent Price: $7.86

Industry: Biotechnology

CEO: Mr. Andrew Obenshain

Sector: Healthcare

Employees: 375

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Leadership

  • Sarah Alspach, Senior Vice President, External Affairs
  • Rich Colvin, MD, PhD, Chief Medical Officer
  • Kasra Kasraian, Senior Vice President, Technical Development and Operations
  • Tom Klima, Chief Commercial & Operating Officer
  • Andrew Obenshain, Chief Executive Officer
  • Scott Shoemaker, Senior Vice President, Quality
  • James Sterling, Chief Financial Officer
  • Joe Vittiglio, Chief Business and Legal Officer
  • Andrea Walton, Chief People Officer
  • Leslie Wilder, Vice President, Head of Regulatory Science
  • Mark Vachon, Chairman; Formerly of GE
  • John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
  • Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
  • Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
  • Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
  • Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
  • Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
  • Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare

Last updated: 2024-12-31

Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Ik T-148009

Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders. Their product pipeline includes treatments for neurological and cancer-related conditions.

Tags: Cancer Treatment, Neurological Disorders, Parkinson's Disease, Pharmaceutical, Therapeutics

Symbol: IKT

Recent Price: $3.24

Industry: Biotechnology

CEO: Dr. Milton H. Werner Ph.D.

Sector: Healthcare

Employees: 8

Address: 3350 Riverwood Parkway SE, Atlanta, GA 30339

Phone: 678 392 3419

Leadership

  • Milton H. Werner, Ph.D., President and CEO
  • C. Warren Olanow MD, FRCPC, FRCP (Hon.), Medical Consultant and CEO of Clintrex Research Corporation
  • Garth Lees-Rolfe, CPA, Chief Financial Officer
  • Dan Williams, Controller
  • Terence Kelly, Ph.D., Medicinal Chemistry Consultant
  • Surendra Singh, Ph.D., Chemistry and Manufacturing Controls
  • Merrill M. Kraines, Partner, McDermott, Will & Emery, Outside General Counsel
  • Roberto Bellini, Managing Partner at BSQUARED Capital
  • Dennis Berman, Serial Entrepreneur
  • David Canner, Ph.D., Partner at Soleus Capital
  • Roy Freeman, M.D., Professor of Neurology at the Harvard Medical School, Director of the Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
  • Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics
  • Amit Munshi, Chief Executive Officer of Orna Therapeutics

Last updated: 2024-12-31

Immuneering Corporation

Immuneering Corporation logo
Market Cap: Lowest
Employees: Low

IMM-1-104 and IMM-6-415

Immuneering Corporation is a biopharmaceutical company focused on developing oncology and neuroscience product candidates, with key products like IMM-1-104 for cancer treatment and IMM-6-415 for solid tumors.

Tags: biopharmaceutical, cancer treatment, drug development, neuroscience, oncology

Symbol: IMRX

Recent Price: $2.25

Industry: Biotechnology

CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

Sector: Healthcare

Employees: 66

Address: 245 Main Street, Cambridge, MA 02142

Phone: 617 500 8080

Last updated: 2024-12-31

Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

VAL-083, REM-001

Kintara Therapeutics is a clinical stage drug development company focused on developing and commercializing anti-cancer therapies for drug-resistant solid tumors.

Tags: REM-001, VAL-083, anti-cancer therapies, clinical stage, drug development

Symbol: KTRA

Recent Price: $0.22

Industry: Biotechnology

CEO: Mr. Jeffrey A. Bacha B.Sc., M.B.A.

Sector: Healthcare

Employees: 1

Address: 12707 High Bluff Drive, San Diego, CA 92130

Phone: 858 350 4364

Leadership

  • Robert E. Hoffman, President, CEO, CFO and Chairman of the Board
  • Greg A. Johnson, (Acting) Head of Operations
  • Laura Johnson, Director
  • Tamara A. Favorito, Director
  • Robert J. Toth, Jr., M.B.A., Director

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

TG Therapeutics, Inc.

TG Therapeutics, Inc. logo
Market Cap: High
Employees: Low

Ublituximab, Umbralisib, Cosibelimab, TG-1701, TG-1801

TG Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.

Tags: B-cell malignancies, BTK inhibitor, Cosibelimab, Ublituximab, Umbralisib, autoimmune diseases, biopharmaceutical

Symbol: TGTX

Recent Price: $31.45

Industry: Biotechnology

CEO: Mr. Michael S. Weiss Esq.

Sector: Healthcare

Employees: 264

Address: 2 Gansevoort Street, New York, NY 10014

Phone: 212 554 4484

Leadership

  • Michael S. Weiss, Chairman, President, and Chief Executive Officer
  • Sean A. Power, CPA, Chief Financial Officer
  • Adam Waldman, Chief Commercialization Officer

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. logo
Market Cap: High
Employees: Medium

AG10, BBP-265, BBP-831, BBP-631, Encaleret

Bridge Bio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases, with a pipeline of 30 programs including candidates like AG10, BBP-265, and others in various stages of clinical trials.

Tags: biopharmaceuticals, clinical trials, drug development, genetic diseases

Symbol: BBIO

Recent Price: $27.32

Industry: Biotechnology

CEO: Dr. Neil Kumar Ph.D.

Sector: Healthcare

Employees: 550

Address: 421 Kipling Street, Palo Alto, CA 94301

Phone: 650 391 9740

Last updated: 2024-12-31

Nektar Therapeutics

Nektar Therapeutics logo
Market Cap: Low
Employees: Low

Bempegaldesleukin

Nektar Therapeutics is a biopharmaceutical company focused on developing medicines for unmet medical needs. Their products include Bempegaldesleukin, an IL-2 pathway agonist in clinical trials for various cancers and COVID-19, and NKTR-358, a cytokine Treg stimulant for autoimmune diseases.

Tags: autoimmune diseases, biopharmaceutical, clinical trials, medicines, oncology

Symbol: NKTR

Recent Price: $0.94

Industry: Biotechnology

CEO: Mr. Howard W. Robin

Sector: Healthcare

Employees: 137

Address: 455 Mission Bay Boulevard South, San Francisco, CA 94158

Phone: 415 482 5300

Leadership

  • Howard W. Robin, President & Chief Executive Officer
  • Robert Bacci, Senior Vice President, HR and Facilities Operations
  • Sandra Gardiner, Chief Financial Officer
  • Jennifer Ruddock, Chief Business Officer
  • Mary Tagliaferri, M.D., Chief Medical Officer
  • Mark A. Wilson, Chief Legal Officer
  • Jonathan Zalevsky, Ph.D., Chief Research & Development Officer

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31